| NCT04034251 |
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT04034251 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2026-05-30 |
| NCT03378128 |
Debulking Surgery in Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03378128 |
Recruiting |
Case Comprehensive Cancer Center |
2020-08-31 |
| NCT03304210 |
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03304210 |
Recruiting |
University Hospital, Ghent |
2020-09-21 |
| NCT03287375 |
Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy - |
https://ClinicalTrials.gov/show/NCT03287375 |
Recruiting |
Odense University Hospital |
2020-12-01 |
| NCT03280511 |
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients |
https://ClinicalTrials.gov/show/NCT03280511 |
Recruiting |
Odense University Hospital |
2022-10-01 |
| NCT03252938 |
Feasibility and Safety of IMP321 for Advanced Stage Solid Tumors |
https://ClinicalTrials.gov/show/NCT03252938 |
Active, not recruiting |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2021-04-30 |
| NCT03246321 |
PIPAC for Peritoneal Metastases of Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT03246321 |
Completed |
Catharina Ziekenhuis Eindhoven |
2019-10-01 |
| NCT03245892 |
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03245892 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-08-31 |
| NCT03188432 |
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03188432 |
Recruiting |
Wake Forest University Health Sciences |
2020-11-01 |
| NCT03127774 |
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma |
https://ClinicalTrials.gov/show/NCT03127774 |
Recruiting |
Columbia University |
2022-05-31 |
| NCT03073694 |
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT03073694 |
Recruiting |
University of Kansas Medical Center |
2020-07-31 |
| NCT02948426 |
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02948426 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-04-01 |
| NCT02891447 |
Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer |
https://ClinicalTrials.gov/show/NCT02891447 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-09-01 |
| NCT02865811 |
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02865811 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-02-28 |
| NCT02855944 |
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients |
https://ClinicalTrials.gov/show/NCT02855944 |
Recruiting |
Clovis Oncology, Inc. |
2022-06-30 |
| NCT02840331 |
Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis |
https://ClinicalTrials.gov/show/NCT02840331 |
Recruiting |
University Hospital Tuebingen |
2019-12-31 |
| NCT02823860 |
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies |
https://ClinicalTrials.gov/show/NCT02823860 |
Recruiting |
Hospices Civils de Lyon |
2022-10-31 |
| NCT02786524 |
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy |
https://ClinicalTrials.gov/show/NCT02786524 |
Completed |
University of Michigan |
2017-10-31 |
| NCT02759588 |
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02759588 |
Recruiting |
Genelux Corporation |
2020-07-31 |
| NCT02758951 |
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases |
https://ClinicalTrials.gov/show/NCT02758951 |
Recruiting |
Catharina Ziekenhuis Eindhoven |
2024-08-01 |
| NCT02739698 |
Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia |
https://ClinicalTrials.gov/show/NCT02739698 |
Completed |
Maimónides Biomedical Research Institute of Córdoba |
2014-11-30 |
| NCT02726997 |
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) |
https://ClinicalTrials.gov/show/NCT02726997 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-07-30 |
| NCT02713386 |
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02713386 |
Active, not recruiting |
NRG Oncology |
2020-09-30 |
| NCT02659241 |
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02659241 |
Recruiting |
M.D. Anderson Cancer Center |
2021-12-31 |
| NCT02638051 |
Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT |
https://ClinicalTrials.gov/show/NCT02638051 |
Completed |
Galenic Research Institute Ltd |
2014-12-31 |
| NCT02606305 |
Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02606305 |
Active, not recruiting |
ImmunoGen, Inc. |
2021-01-31 |
| NCT02650986 |
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 |
https://ClinicalTrials.gov/show/NCT02650986 |
Recruiting |
Roswell Park Cancer Institute |
2021-06-20 |
| NCT03172416 |
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT03172416 |
Recruiting |
National University Hospital, Singapore |
2022-12-31 |
| NCT03038100 |
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03038100 |
Active, not recruiting |
Hoffmann-La Roche |
2020-03-30 |
| NCT02571725 |
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02571725 |
Recruiting |
New Mexico Cancer Care Alliance |
2020-02-29 |
| NCT01970722 |
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01970722 |
Recruiting |
City of Hope Medical Center |
2021-05-19 |
| NCT02520154 |
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02520154 |
Recruiting |
M.D. Anderson Cancer Center |
2020-07-31 |
| NCT02475772 |
A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT02475772 |
Completed |
Ruhr University of Bochum |
2018-05-31 |
| NCT02463877 |
A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy |
https://ClinicalTrials.gov/show/NCT02463877 |
Active, not recruiting |
University of California, San Diego |
2023-09-30 |
| NCT02356471 |
Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery |
https://ClinicalTrials.gov/show/NCT02356471 |
Completed |
Wake Forest University Health Sciences |
2016-10-31 |
| NCT02320448 |
Treating Peritoneal Carcinomatosis With PIPAC |
https://ClinicalTrials.gov/show/NCT02320448 |
Completed |
Odense University Hospital |
2017-08-31 |
| NCT02316834 |
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02316834 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-02-01 |
| NCT02311907 |
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02311907 |
Completed |
Alliance for Clinical Trials in Oncology |
2012-08-31 |
| NCT02272790 |
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02272790 |
Active, not recruiting |
AstraZeneca |
2018-12-13 |
| NCT02231086 |
Adjuvant HIPEC in High Risk Colon Cancer |
https://ClinicalTrials.gov/show/NCT02231086 |
Active, not recruiting |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2018-09-30 |
| NCT02219893 |
Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial |
https://ClinicalTrials.gov/show/NCT02219893 |
Completed |
Oslo University Hospital |
2016-12-10 |
| NCT02179489 |
Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT02179489 |
Recruiting |
Zhejiang University |
2019-10-31 |
| NCT02158988 |
Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT02158988 |
Active, not recruiting |
Charite University, Berlin, Germany |
2020-10-31 |
| NCT02151448 |
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies |
https://ClinicalTrials.gov/show/NCT02151448 |
Completed |
University of Pittsburgh |
2019-02-18 |
| NCT02142803 |
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02142803 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-06-30 |
| NCT02122185 |
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02122185 |
Recruiting |
University of Chicago |
2021-02-25 |
| NCT02111941 |
Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy |
https://ClinicalTrials.gov/show/NCT02111941 |
Active, not recruiting |
Mayo Clinic |
2017-08-18 |
| NCT01314105 |
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01314105 |
Completed |
Boehringer Ingelheim |
2013-07-31 |
| NCT01313078 |
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01313078 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-09-30 |
| NCT01312389 |
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01312389 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2012-05-31 |
| NCT02042430 |
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02042430 |
Active, not recruiting |
National Cancer Institute (NCI) |
2016-03-31 |
| NCT02040142 |
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C |
https://ClinicalTrials.gov/show/NCT02040142 |
Recruiting |
Albert Einstein College of Medicine |
2021-11-30 |
| NCT02032485 |
Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT02032485 |
Completed |
Jules Bordet Institute |
2014-09-30 |
| NCT02020707 |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers |
https://ClinicalTrials.gov/show/NCT02020707 |
Recruiting |
Mayo Clinic |
2020-10-03 |
| NCT03834272 |
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies |
https://ClinicalTrials.gov/show/NCT03834272 |
Active, not recruiting |
Lumicell, Inc. |
2020-12-01 |
| NCT01891344 |
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) |
https://ClinicalTrials.gov/show/NCT01891344 |
Active, not recruiting |
Clovis Oncology, Inc. |
2019-11-05 |
| NCT01883297 |
“Re-Stimulated” Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01883297 |
Active, not recruiting |
University Health Network, Toronto |
2023-06-30 |
| NCT01882920 |
Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec) |
https://ClinicalTrials.gov/show/NCT01882920 |
Completed |
Regina Elena Cancer Institute |
2012-06-30 |
| NCT01853644 |
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01853644 |
Active, not recruiting |
Northwestern University |
2018-10-02 |
| NCT01846611 |
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01846611 |
Completed |
Janssen Research & Development, LLC |
2018-01-18 |
| NCT01834469 |
Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT01834469 |
Completed |
Jules Bordet Institute |
2014-10-31 |
| NCT01833832 |
Surgery and Heated Chemotherapy for Adrenocortical Carcinoma |
https://ClinicalTrials.gov/show/NCT01833832 |
Completed |
National Institutes of Health Clinical Center (CC) |
2018-08-09 |
| NCT01767675 |
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01767675 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT01764802 |
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer |
https://ClinicalTrials.gov/show/NCT01764802 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-06-01 |
| NCT01764789 |
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer |
https://ClinicalTrials.gov/show/NCT01764789 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-01-31 |
| NCT01666444 |
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01666444 |
Completed |
Celgene |
2016-07-31 |
| NCT01652079 |
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01652079 |
Completed |
Massachusetts General Hospital |
2018-03-31 |
| NCT02024841 |
Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT02024841 |
Completed |
The University of Hong Kong |
2017-02-28 |
| NCT01606241 |
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01606241 |
Completed |
Mayo Clinic |
2014-09-25 |
| NCT01579812 |
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients |
https://ClinicalTrials.gov/show/NCT01579812 |
Completed |
University of Michigan Rogel Cancer Center |
2017-06-30 |
| NCT01560533 |
Representation of the Body for Patients With Cancer |
https://ClinicalTrials.gov/show/NCT01560533 |
Completed |
Hospices Civils de Lyon |
2013-01-31 |
| NCT01536054 |
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT01536054 |
Completed |
Roswell Park Cancer Institute |
2015-04-21 |
| NCT01524094 |
Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT01524094 |
Completed |
Uppsala University |
2010-12-31 |
| NCT01504256 |
Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas |
https://ClinicalTrials.gov/show/NCT01504256 |
Completed |
AIO-Studien-gGmbH |
2017-03-31 |
| NCT01504126 |
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01504126 |
Completed |
M.D. Anderson Cancer Center |
2019-08-15 |
| NCT01478685 |
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01478685 |
Completed |
Celgene |
2015-11-17 |
| NCT01462890 |
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01462890 |
Active, not recruiting |
AGO Study Group |
2018-11-30 |
| NCT01443260 |
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT01443260 |
Completed |
Genelux Corporation |
2014-09-30 |
| NCT01416038 |
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01416038 |
Completed |
ImmunoVaccine Technologies, Inc. (IMV Inc.) |
2013-05-31 |
| NCT03348150 |
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. |
https://ClinicalTrials.gov/show/NCT03348150 |
Recruiting |
The Netherlands Cancer Institute |
2020-10-01 |
| NCT01384253 |
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy |
https://ClinicalTrials.gov/show/NCT01384253 |
Completed |
Orano Med LLC |
2015-10-31 |
| NCT01379482 |
Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer |
https://ClinicalTrials.gov/show/NCT01379482 |
Completed |
Uppsala University |
2009-03-31 |
| NCT01339650 |
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01339650 |
Completed |
AbbVie |
2017-11-30 |
| NCT04370925 |
Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT04370925 |
Recruiting |
Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
2024-04-30 |
| NCT04232384 |
Comparison of "Roll-over’ Technique With Standard Abdominal Paracentesis in Suspected Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT04232384 |
Recruiting |
Postgraduate Institute of Medical Education and Research |
2021-11-15 |
| NCT04231175 |
Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT04231175 |
Recruiting |
The Netherlands Cancer Institute |
2023-10-28 |
| NCT04158349 |
Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer |
https://ClinicalTrials.gov/show/NCT04158349 |
Recruiting |
University of Utah |
2023-01-30 |
| NCT04107077 |
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer |
https://ClinicalTrials.gov/show/NCT04107077 |
Recruiting |
University of Chicago |
2023-06-01 |
| NCT04047771 |
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT04047771 |
Recruiting |
Sichuan Clover Biopharmaceuticals, Inc. |
2021-05-31 |
| NCT04029909 |
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT04029909 |
Recruiting |
Lee’s Pharmaceutical Limited |
2019-12-31 |
| NCT03976999 |
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers |
https://ClinicalTrials.gov/show/NCT03976999 |
Recruiting |
Institut du Cancer de Montpellier - Val d’Aurelle |
2020-07-31 |
| NCT03968406 |
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers |
https://ClinicalTrials.gov/show/NCT03968406 |
Recruiting |
M.D. Anderson Cancer Center |
2021-10-11 |
| NCT03943173 |
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery |
https://ClinicalTrials.gov/show/NCT03943173 |
Recruiting |
M.D. Anderson Cancer Center |
2021-03-03 |
| NCT03907527 |
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03907527 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-04-01 |
| NCT03777943 |
Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT03777943 |
Recruiting |
University Hospital, Ghent |
2020-12-31 |
| NCT03732781 |
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC |
https://ClinicalTrials.gov/show/NCT03732781 |
Recruiting |
Oncoinvent AS |
2022-12-31 |
| NCT03699332 |
Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin |
https://ClinicalTrials.gov/show/NCT03699332 |
Recruiting |
Radboud University |
2021-03-31 |
| NCT03693248 |
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03693248 |
Recruiting |
Seoul National University Hospital |
2023-12-31 |
| NCT03682744 |
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) |
https://ClinicalTrials.gov/show/NCT03682744 |
Active, not recruiting |
Sorrento Therapeutics, Inc. |
2020-09-30 |
| NCT03663712 |
Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies |
https://ClinicalTrials.gov/show/NCT03663712 |
Recruiting |
Duke University |
2021-03-01 |
| NCT03635489 |
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03635489 |
Active, not recruiting |
Hoffmann-La Roche |
2020-12-29 |
| NCT03618758 |
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 |
https://ClinicalTrials.gov/show/NCT03618758 |
Recruiting |
Seoul National University Bundang Hospital |
2020-12-31 |
| NCT03517852 |
Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC) |
https://ClinicalTrials.gov/show/NCT03517852 |
Active, not recruiting |
Mayo Clinic |
2019-12-31 |
| NCT03430700 |
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03430700 |
Recruiting |
University College, London |
2020-11-16 |
| NCT01264432 |
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01264432 |
Completed |
National Cancer Institute (NCI) |
2016-11-15 |
| NCT01248962 |
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01248962 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-08-31 |
| NCT01248273 |
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission |
https://ClinicalTrials.gov/show/NCT01248273 |
Completed |
Memorial Sloan Kettering Cancer Center |
2017-03-31 |
| NCT01204749 |
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01204749 |
Completed |
Amgen |
2013-03-31 |
| NCT01188876 |
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01188876 |
Completed |
Massachusetts General Hospital |
2016-07-31 |
| NCT01167712 |
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01167712 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-12-01 |
| NCT01105650 |
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01105650 |
Completed |
Masonic Cancer Center, University of Minnesota |
2014-04-30 |
| NCT01091428 |
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer |
https://ClinicalTrials.gov/show/NCT01091428 |
Completed |
Takeda |
2014-08-12 |
| NCT01061515 |
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT01061515 |
Active, not recruiting |
Washington University School of Medicine |
2020-09-27 |
| NCT01015118 |
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01015118 |
Completed |
Boehringer Ingelheim |
2013-04-01 |
| NCT01010126 |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
https://ClinicalTrials.gov/show/NCT01010126 |
Completed |
National Cancer Institute (NCI) |
2017-03-13 |
| NCT00989651 |
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00989651 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-09-01 |
| NCT00954174 |
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00954174 |
Active, not recruiting |
Gynecologic Oncology Group |
2019-03-30 |
| NCT00951496 |
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00951496 |
Active, not recruiting |
National Cancer Institute (NCI) |
2016-01-11 |
| NCT00857545 |
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission |
https://ClinicalTrials.gov/show/NCT00857545 |
Completed |
Gynecologic Oncology Group |
2015-09-30 |
| NCT02833753 |
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI |
https://ClinicalTrials.gov/show/NCT02833753 |
Recruiting |
University of Massachusetts, Worcester |
2020-08-31 |
| NCT03253133 |
Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC |
https://ClinicalTrials.gov/show/NCT03253133 |
Recruiting |
Institut du Cancer de Montpellier - Val d’Aurelle |
2019-12-31 |
| NCT00801320 |
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00801320 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-08-31 |
| NCT02903771 |
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. |
https://ClinicalTrials.gov/show/NCT02903771 |
Completed |
Kazia Therapeutics Limited |
2020-03-24 |
| NCT03150992 |
EDMONd - Elemental Diet in Bowel Obstruction |
https://ClinicalTrials.gov/show/NCT03150992 |
Recruiting |
Royal Surrey County Hospital NHS Foundation Trust |
2019-12-31 |
| NCT02658214 |
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02658214 |
Completed |
AstraZeneca |
2019-11-14 |
| NCT02578888 |
Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies |
https://ClinicalTrials.gov/show/NCT02578888 |
Completed |
Albert Einstein College of Medicine |
2016-05-31 |
| NCT03740165 |
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43) |
https://ClinicalTrials.gov/show/NCT03740165 |
Recruiting |
Merck Sharp & Dohme Corp. |
2025-08-08 |
| NCT04220827 |
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer |
https://ClinicalTrials.gov/show/NCT04220827 |
Recruiting |
M.D. Anderson Cancer Center |
2022-11-01 |
| NCT03508570 |
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT03508570 |
Recruiting |
M.D. Anderson Cancer Center |
2021-01-01 |
| NCT00769405 |
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT00769405 |
Completed |
UNICANCER |
2015-12-31 |
| NCT00719303 |
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00719303 |
Recruiting |
Gynecologic Oncology Group |
2020-12-31 |
| NCT00698451 |
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers |
https://ClinicalTrials.gov/show/NCT00698451 |
Completed |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2010-10-31 |
| NCT00683241 |
A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00683241 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2009-12-31 |
| NCT00677079 |
Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00677079 |
Completed |
Sanofi |
2008-12-31 |
| NCT00666991 |
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers |
https://ClinicalTrials.gov/show/NCT00666991 |
Completed |
CritiTech, Inc. |
2013-05-31 |
| NCT00616941 |
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00616941 |
Completed |
Ludwig Institute for Cancer Research |
2011-06-30 |
| NCT00569673 |
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00569673 |
Completed |
Gynecologic Oncology Group |
2012-01-31 |
| NCT00562640 |
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) |
https://ClinicalTrials.gov/show/NCT00562640 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-12-31 |
| NCT00520013 |
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors |
https://ClinicalTrials.gov/show/NCT00520013 |
Completed |
Dana-Farber Cancer Institute |
2010-10-31 |
| NCT00517621 |
Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire |
https://ClinicalTrials.gov/show/NCT00517621 |
Completed |
ARCAGY/ GINECO GROUP |
2010-09-30 |
| NCT00504257 |
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma |
https://ClinicalTrials.gov/show/NCT00504257 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2012-10-31 |
| NCT00491855 |
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT00491855 |
Completed |
M.D. Anderson Cancer Center |
2012-12-31 |
| NCT00489359 |
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00489359 |
Completed |
Eli Lilly and Company |
2010-02-28 |
| NCT00483782 |
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00483782 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00479817 |
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00479817 |
Completed |
Amgen |
2009-08-11 |
| NCT00443196 |
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas |
https://ClinicalTrials.gov/show/NCT00443196 |
Completed |
Pierian Biosciences |
NA |
| NCT00437502 |
A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00437502 |
Completed |
Duke University |
2010-01-31 |
| NCT00436657 |
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00436657 |
Completed |
M.D. Anderson Cancer Center |
2011-04-30 |
| NCT00436501 |
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00436501 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00436215 |
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00436215 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-06-26 |
| NCT00391118 |
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (“Sugar Pill”) |
https://ClinicalTrials.gov/show/NCT00391118 |
Completed |
Eli Lilly and Company |
2010-04-30 |
| NCT00388037 |
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00388037 |
Completed |
National Cancer Institute (NCI) |
2012-01-31 |
| NCT00382811 |
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00382811 |
Completed |
MEI Pharma, Inc. |
2009-04-30 |
| NCT00348699 |
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00348699 |
Completed |
National Cancer Institute (NCI) |
2013-01-31 |
| NCT00332696 |
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT00332696 |
Completed |
Novartis |
2008-09-30 |
| NCT00318370 |
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT00318370 |
Completed |
Morphotek |
2010-02-28 |
| NCT00317772 |
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00317772 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-09-04 |
| NCT00314678 |
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00314678 |
Completed |
University of California, Irvine |
NA |
| NCT00267696 |
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00267696 |
Completed |
Ohio State University Comprehensive Cancer Center |
2013-09-30 |
| NCT00262990 |
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00262990 |
Completed |
Novartis |
2010-02-28 |
| NCT00262847 |
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00262847 |
Completed |
National Cancer Institute (NCI) |
2010-11-30 |
| NCT00217568 |
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00217568 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-03-31 |
| NCT00217555 |
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00217555 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-02-28 |
| NCT00216372 |
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT00216372 |
Completed |
Ipsen |
2008-10-31 |
| NCT00191646 |
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy |
https://ClinicalTrials.gov/show/NCT00191646 |
Completed |
Eli Lilly and Company |
2009-08-31 |
| NCT00191607 |
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. |
https://ClinicalTrials.gov/show/NCT00191607 |
Completed |
Eli Lilly and Company |
NA |
| NCT00189566 |
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse |
https://ClinicalTrials.gov/show/NCT00189566 |
Completed |
ARCAGY/ GINECO GROUP |
NA |
| NCT00189345 |
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT00189345 |
Completed |
AGO Study Group |
NA |
| NCT00183794 |
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma |
https://ClinicalTrials.gov/show/NCT00183794 |
Completed |
University of Southern California |
2009-05-31 |
| NCT00138242 |
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00138242 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00132067 |
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00132067 |
Completed |
National Cancer Institute (NCI) |
2006-08-31 |
| NCT00126542 |
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00126542 |
Completed |
National Cancer Institute (NCI) |
2007-01-31 |
| NCT00112086 |
OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 |
https://ClinicalTrials.gov/show/NCT00112086 |
Completed |
Japan Clinical Oncology Group |
2007-02-28 |
| NCT00108745 |
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00108745 |
Active, not recruiting |
Gynecologic Oncology Group |
2022-01-01 |
| NCT00103545 |
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response |
https://ClinicalTrials.gov/show/NCT00103545 |
Completed |
AGO Study Group |
NA |
| NCT00093496 |
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00093496 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00083122 |
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00083122 |
Completed |
National Cancer Institute (NCI) |
2010-07-31 |
| NCT00075712 |
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00075712 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00074867 |
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00074867 |
Completed |
Pfizer |
NA |
| NCT00063401 |
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00063401 |
Completed |
Eli Lilly and Company |
2006-06-30 |
| NCT00061308 |
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00061308 |
Completed |
GlaxoSmithKline |
2004-09-30 |
| NCT00059618 |
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00059618 |
Completed |
M.D. Anderson Cancer Center |
2007-04-30 |
| NCT00052962 |
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT00052962 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-09-30 |
| NCT00045175 |
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00045175 |
Completed |
University Health Network, Toronto |
2013-06-30 |
| NCT00026091 |
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00026091 |
Completed |
National Cancer Institute (NCI) |
2004-03-31 |
| NCT00006155 |
SU5416 and Carboplatin to Treat Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00006155 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001332 |
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT00001332 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00035100 |
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00035100 |
Completed |
Novartis |
2003-06-30 |
| NCT00004547 |
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy |
https://ClinicalTrials.gov/show/NCT00004547 |
Completed |
National Institutes of Health Clinical Center (CC) |
2009-08-31 |
| NCT00001569 |
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT00001569 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |